Clinical Trial Update: 0822GCC: Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating apricoxib or placebo with docetaxel or pemetrexed in non-small cell lung cancer has completed with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Apricoxib (apricoxib)
• DOCETAXEL (DOCETAXEL)
• Pemetrexed (pemetrexed)

Snippet

Sponsor: University of Maryland, Baltimore | Conditions: Lung Cancer, Non Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2013-07-22